Business Wire

TRIPLE-1-INC.

4.2.2020 12:02:06 CET | Business Wire | Press release

Share
TRIPLE-1 Inc., Announcement of Two New Products That Use Cutting Edge 7 nm Process and 5 nm Process

TRIPLE-1 Inc. (Headquarters: Hakata-ku, Fukuoka-shi, Fukuoka; Representative Director CEO: Takuya Yamaguchi; Henceforth: TRIPLE-1) has announced two new products: The ASIC "KAMIKAZE Ⅱ" for Bitcoin mining that uses a 7 nm process made by TSMC, and the AI processor "GOKU" for deep learning that uses the world's leading 5 nm process.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005385/en/

--- Overview

In the "cryptocurrency mining market" that is driving the miniaturization of semiconductor processes in recent years, an extremely severe business model has been formed that directly links the power performance of semiconductors used for mining with mining proceeds. Starting in February 2017, TRIPLE-1 has been using core know-how involving the designability for cutting edge processes, the optimization of electrical consumption, and the improvement of the yield rate that have been fostered from the development of ASIC (application-specific integrated circuits) for cryptocurrency mining. Development has started on both "KAMIKAZE Ⅱ", the latest high-performance ASIC for Bitcoin mining that uses a 7 nm process made by TSMC, and the AI processor "GOKU" for deep learning that uses the world's leading 5 nm process.

--- Next generation 7 nm Bitcoin mining ASIC "KAMIKAZE Ⅱ" – That design completed

By making use of the know-how fostered from the initial "KAMIKAZE" model, the design for the next generation model "KAMIKAZE Ⅱ" has been finalized. After tape outing to TSMC and the prototype has been inspected, we will start mass production from 2021.

Additionally, we have started to offer reference boards and reference designs for the first "KAMIKAZE" mining machine model, the system that can provide smoother installation support is ready.

< Feature > ASIC Boost is built-in, improving the mining efficiency rapidly

By loading the custom algorithm "ASIC Boost" that improves mining efficiency (it was not loaded on to the first “KAMIKAZE” model), a more highly efficient mining environment is provided. Additionally, by supporting ultra-low voltage drive (supplied voltage 0.2x V), we anticipate a drastic reduction in electrical consumption.

KAMIKAZE / KAMIKAZE Ⅱ Performance specifications comparison

 

KAMIKAZE

KAMIKAZE Ⅱ

Process

TSMC 7 nm

TSMC 7 nm improved process

Die size

3.5 × 3.9 mm

3.0 × 9.0 mm

Package

7 × 7 mm FC-BGA

7 × 12 mm FC-LGA

Input voltage

0.3 V or less

Drives at a lower voltage than KAMIKAZE

Power consumption

1.2 W / chip

6.7 W / chip

Hash rate

23 GHs / chip

240 GHs / chip

Electrical efficiency

52 W / THs

28 W / THs

ASIC Boost

None

Supported

*KAMIKAZE: Chip actual value, KAMIKAZEⅡ: Design target

--- New challenges, enter the AI market

In recent years, various companies have entered the AI chip market, including not only giant IT companies but also fast-growing start-ups in China. As competition for edge AI chip development intensifies, oligopoly supply by several major companies continues in the deep learning AI processor market. Currently there are no mass-produced chips smaller than 12 nm process.

On the other hand, the electrical consumption of data centers is expected to excess 10% of the entire world's electrical energy by 2030. TRIPLE-1 believe that AI processors for deep learning need not only high "computing power" to learn and process a huge amount of data, but also a severe viewpoint on "power consumption" from the viewpoint of energy conservation and cost reduction.

Therefore TRIPLE-1 has launched the project to develop "GOKU", an ultra-low power consumption dedicated deep learning AI processor using the world's most advanced 5nm process, utilizing our unique Low power / High performance technology and design know-how in the most advanced processes.

--- "GOKU", an AI processor for deep learning with the world's leading 5 nm process

The first stage prototype has been completed, and we are inspecting the performance. Realizing the mass production in 2021, we will complete the prototypes closer to mass-produced products within 2020. It will be sold to the equipment and devices manufacturers for data servers or deep learning centers around the world, and we have already begun to discuss with multiple companies.

< Feature > Using the world's leading 5 nm process, it has 10 times higher power efficiency than conventional

Our goal is to reduce power consumption by 1/10 of the equivalent performance compared to conventional products (process: 12 nm), and its feature is low-voltage operation that is inconceivable with existing products.

< Feature > Design to connect multiple calculation units

Like the structure of the human brain, where synapses connect neurons in a complex manner, great amount and very complex inter-core communication is important for deep learning AI processors.

Utilizing the unique circuit design technology of "GOKU", which arranges many small arithmetic units on one large die as much as possible, it is designed to secure the communication (interconnect) band between the arithmetic units as much as possible.

It has been designed to get closer to the human brain.

< Reference > GOKU performance table (Design target)

Process

5 nm

Power consumption

100 W

Peak performance (half-precision)

1 PFLOPS (1,000 TFLOPS)

Electrical efficiency (half-precision)

10 TFLOPS / W

--- TRIPLE-1 outline

Company Name: TRIPLE-1, Inc.
Corporate Headquarter:
7F IT Bldg.Ⅱ,1-14-20 Hakataeki-Higashi, Hakata-ku Fukuoka-shi, Fukuoka, Japan
Representatives: Representative Director CEO Takuya Yamaguchi
The capital: 3662 million 895 thousand and 398 yen (including the capital reserve)

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye